Consortium members
UD-GenoMed Ltd.

UD-GenoMed Ltd. was founded by the University of Debrecen with the ultimate goal to develop its genomic technology base and additional services previously provided exclusively by the Clinical Genomic Center of UD. Its main field of operation is functional genomics and high throughput expression profiling, database development, data integration and mining and works primarily as an R&D service provider with the potential to expand its activity to pre-clinical and clinical studies and also to biomarker research.
It possesses several know-hows in the fields of clinical study coordination, sample collection, biobanking and expression data interpretation and clinical and molecular data integration. It is supported by the human resources of the University, which ensures its competence and expertise in research projects consisting clinical study design and execution, large scale biobanking, data integration and interpretation. UD-GenoMed Ltd. intends to be an interface between the private sector and the Medical and Health Science Center by mediating research collaborations through the utilization of the local knowledge inside the institution and a professional management, which intensively maintains and makes relationships primarily with pharmaceutical and biotech companies. For more information visit:

Gedeon Richter Plc.

Gedeon Richter, headquartered in Budapest/Hungary, is a major pharmaceutical company in Hungary and one of the largest in Central Eastern Europe, with consolidated sales of 1.2 billion USD in 2007, and 4 billion USD market capitalization. The Company was founded in 1901. Richter is a regional multinational company in Central Eastern Europe and in the CIS, and has a growing presence through its commercial subsidiaries in key EU countries, Japan and the USA. More than 80% of its annual sales of USD 934 million in 2007 were exported to 80 countries (Russia, EU, USA, Japan, etc.). The Company has a worldwide presence through its representative offices, commercial subsidiaries and joint ventures in 30 countries. Apart from Hungarian production sites at Budapest and Dorog, the Company has manufacturing facilities in Russia, Romania, Poland and India.
The Company’s product portfolio includes more than 100 products, offering effective and advanced treatment for almost all therapeutic areas. Based on its traditional skills in steroid chemistry, the Company plays a significant  role in the gynecological field worldwide. Richter is one of the few companies in the world, which offers a comprehensive gynecological portfolio including the most advanced oral contraceptives, emergency contraceptives, antifungal and hormone replacement therapy products. A significant part of the Company’s turnover results from original drug research and development activity, is currently focused on diseases of the central nervous system. Apart from original research, Richter is engaged in chemical process development and generics development.
The Company has received various innovation awards as an acknowledgement of its outstanding achievement in innovation. Besides playing a significant role in Hungarian economy, Richter is a major participant of community life, too. The Company believes it should dedicate its efforts to the areas strongly connected to its business activity. Therefore, Richter is an avid supporter of health care and educational sectors. For more information, please visit:

Astrid Research Inc.

Astrid Research Inc. is a privately held bioinformatics company (SME) focusing on -omics research and development - utilizing its core competences in mathematics and information technologies.
The firm was founded in December 2004 under the name Kripto Research Inc, as one of the first companies to commercialize the cryptographic (technology for data encryption and protection) research results created at the University of Debrecen.
In 2006 the company's focus shifted to medical and health informatics utilizing its strong research background in data protection and security. Reacting to that shift the company changed its name to Astrid Research. During this time several software applications were developed supporting telemedicine, patient compliance and therapy adjustment. Astrid started research in medical image processing in 2007, its first project being the automated detection of melanoma malignum from a digital image. Later that year, as the personalized medicine era started to enter, the company put more and more efforts in high throughput data analysis and biostatistics. Astrid partnered with Gedeon Richter (one of the largest pharmaceutical companies in Hungary) and the University of Debrecen in 2008 to develop novel personalized therapy for patients with schizophrenia.
From 2009 Astrid Research Inc. consciously developed IT technologies and know-hows supporting all steps of the preclinical research workflow and various "-omics" technologies enabling our partners to get involved in the creation of molecular diagnostics and personalized therapy. In 2010 responding the growing demand Astrid Research started to develop IT technologies to support projects in the field of energy genomics and syntetic biology. For more visit website at

University of Debrecen

University of Debrecen (est. 1538) is the oldest institution of higher education in continuous operation in Hungary. University of Debrecen has a student body of 29,000, out of which 19,000 are full-time students. More than 1400 instructors teach at the University, making it one of the largest higher education institutions in Hungary. Its 11 university and 4 college faculties, and 21 doctoral schools undoubtedly offer the widest choice of majors and other forms of training. With its research capacity in the Medical and Health Science Center it is the second largest research base in the country in life sciences integrating the Research Center for Molecular Medicine that is recognized as a Center of Excellence by the EU.
The Debrecen Clinical Genomics Center is a core laboratory of the Medical Center with the following main areas of activity: i) biobanking projects, ii) standard genomics services, iii) complex molecular biology diagnostics, iiii) education. For more visit:

The Hungarian Clinical Neurogenetic Society

The Hungarian Clinical Neurogenetic Society (HCNS) was established in 1997 by neurologists, psychiatrists, pediatricians and geneticists interested in the molecular medicine. The president of the society is Maria Judit Molnar MD, PhD since 2001.
The aim of the society is to help its members in making clinical decisions by establishing national guidelines for neurogenetic testing and future therapy and diagnostics to promote national and international collaboration in this field and to advance education of the molecular neurology and psychiatry. To achieve its goals, in the matters of framing the opinion of the society about neurogenetics, the HCNS gives recommendations and professional opinion when decisions, new laws or guidelines are being established or are being modified, forwards them to the competent institutions and cooperates with them.
HCNS helps to promote professional ambitions of its members by establishing educational and research bases. The society has strong connection with similar societies of other nations. It constantly informs its members of current and future neurogenetic testing possibilities, conceptions and regulations. The Society harmonizes the activities of its members. It organizes scientific meetings, national and international congresses, takes part in these and helps its members to attend national and international scientific programs. The Society commits itself in questions concerning studies on human genetics and gene therapy.
The income of the society is made up of the membership fees paid by the members, of donations by supporting members and other private individuals or corporations, and of income from scientific programs.
In 2007 HCNS established a biobank, the NEPSYBANK. The members of the NEPSYBANK are the Departments of Neurology and Psychiatry of the 4 Medical Universities of Hungary. The  departments are collecting biological samples from patients with different neurological and psychiatric disorders (e.g. schizophrenia). For more visit:

Biobankon alapuló biomarker felfedezése és molekuláris mechanizmuskutatása az antipszichotikus gyógyszerek fejlesztésében című projekt hivatalos oldala.

A projektet a Kutatási és Technológiai Innovációs Alap terhére kiírt Nemzeti Technológiai Program Élettudományok alprogramja útján a Nemzeti Kutatási és Technológiai Hivatal támogatja.

Konzorciumi tagok: UD-GenoMed Kft, Richter Gedeon Nyrt, Debreceni Egyetem, Astrid Research Kft, Magyar Klinikai Neurogenetikai Társaság